Johnson & Johnson Aktie
WKN: 853260 / ISIN: US4781601046
06.04.2005 20:18:00
|
FDA Releases Information from Mentor's Silicone Gel Breast Implant Ap
FDA Releases Information from Mentor's Silicone Gel Breast Implant Approval Application
Mentor Corporation (NYSE:MNT), a leading supplier of medical products in the United States and internationally, today announced that the U.S. Food and Drug Administration (FDA) has posted information related to Mentor's silicone gel breast implant pre-market approval (PMA) application, scheduled to be reviewed at a General and Plastics Surgery Devices Advisory Panel meeting April 11-13, 2005, on its web site. The information can be viewed by accessing a link on Mentor's web site, www.mentorcorp.com, or by accessing the FDA web site directly, http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/ cfAdvisory/details.cfm?mtg=593. (Due to its length, this URL may need to be copied/pasted into your Internet browser's address field. Remove the extra space if one exists.)
Mentor's pivotal Core Gel Study followed 1,007 women who were implanted with silicone gel-filled breast implants for either augmentation, reconstruction or revision surgery. The data submitted to the FDA includes information from the 3-year follow-up period as well as longer-term clinical data specific to the integrity of Mentor's silicone gel-filled breast implants.
The FDA General and Plastic Surgery Devices Advisory Panel meeting is scheduled for April 11-13, 2005. Mentor is scheduled to present its data on Wednesday, April 13th.
About Mentor Corporation
Founded in 1969, Mentor Corporation is a leading supplier of medical products for the global healthcare market. The Company develops, manufactures and markets innovative, science-based products for the aesthetics, urologic specialties and clinical and consumer healthcare markets around the world. The Company's website is www.mentorcorp.com.
--30--SW/la*
Business Editors/Health/Medical Writers
SANTA BARBARA, Calif.--(BUSINESS WIRE)--April 6, 2005--Mentor Corporation (NYSE:MNT):
-- | General And Plastic Surgery Devices Advisory Panel Meeting Scheduled for April 11-13, 2005 at the Hilton Washington DC North/Gaithersburg, 620 Perry Pkwy, Gaithersburg, MD |
-- | Mentor To Present Data From Pivotal Core Gel Study On Wednesday, April 13, 2005 |
Mentor Corporation (NYSE:MNT), a leading supplier of medical products in the United States and internationally, today announced that the U.S. Food and Drug Administration (FDA) has posted information related to Mentor's silicone gel breast implant pre-market approval (PMA) application, scheduled to be reviewed at a General and Plastics Surgery Devices Advisory Panel meeting April 11-13, 2005, on its web site. The information can be viewed by accessing a link on Mentor's web site, www.mentorcorp.com, or by accessing the FDA web site directly, http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/ cfAdvisory/details.cfm?mtg=593. (Due to its length, this URL may need to be copied/pasted into your Internet browser's address field. Remove the extra space if one exists.)
Mentor's pivotal Core Gel Study followed 1,007 women who were implanted with silicone gel-filled breast implants for either augmentation, reconstruction or revision surgery. The data submitted to the FDA includes information from the 3-year follow-up period as well as longer-term clinical data specific to the integrity of Mentor's silicone gel-filled breast implants.
The FDA General and Plastic Surgery Devices Advisory Panel meeting is scheduled for April 11-13, 2005. Mentor is scheduled to present its data on Wednesday, April 13th.
About Mentor Corporation
Founded in 1969, Mentor Corporation is a leading supplier of medical products for the global healthcare market. The Company develops, manufactures and markets innovative, science-based products for the aesthetics, urologic specialties and clinical and consumer healthcare markets around the world. The Company's website is www.mentorcorp.com.
--30--SW/la*
CONTACT: Mentor Corporation Peter R. Nicholson, 805-879-6082 (Investors) Sara Allison DeRousse, 805-879-6346 (Media)
KEYWORD: CALIFORNIA MARYLAND INDUSTRY KEYWORD: MEDICAL BANKING CONSUMER/HOUSEHOLD PRODUCT SOURCE: Mentor Corporation
Copyright Business Wire 2005

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
JETZT DEVISEN-CFDS MIT BIS ZU HEBEL 30 HANDELN
Handeln Sie Devisen-CFDs mit kleinen Spreads. Mit nur 100 € können Sie mit der Wirkung von 3.000 Euro Kapital handeln.
82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren.
Nachrichten zu Johnson & Johnsonmehr Nachrichten
08.05.25 |
Optimismus in New York: Dow Jones zum Handelsstart mit Kursplus (finanzen.at) | |
07.05.25 |
Börse New York: Dow Jones mit positivem Vorzeichen (finanzen.at) | |
07.05.25 |
Aufschläge in New York: So entwickelt sich der Dow Jones am Mittwochmittag (finanzen.at) | |
07.05.25 |
Dow Jones 30 Industrial-Titel Johnson Johnson-Aktie: So viel hätten Anleger an einem Johnson Johnson-Investment von vor einem Jahr verdient (finanzen.at) | |
06.05.25 |
NYSE-Handel So entwickelt sich der Dow Jones aktuell (finanzen.at) | |
01.05.25 |
Gute Stimmung in New York: Dow Jones zum Handelsstart fester (finanzen.at) | |
30.04.25 |
Dow Jones 30 Industrial-Papier Johnson Johnson-Aktie: So viel Gewinn hätte ein Johnson Johnson-Investment von vor 10 Jahren abgeworfen (finanzen.at) | |
30.04.25 |
Schwacher Wochentag in New York: Dow Jones fällt zum Start des Mittwochshandels zurück (finanzen.at) |
Analysen zu Johnson & Johnsonmehr Analysen
Aktien in diesem Artikel
Johnson & Johnson | 136,58 | -0,35% |
|
Indizes in diesem Artikel
S&P 600 SmallCap | 935,46 | -0,94% |